Objective To observe the curative effect of modified Yiweitang on anorexia of the Spleen and Stomach Yin deficient type. Methods90 patients with anorexia belonging to spleen yin deficiency type were randomized in to 2 groups, by 1: 1 ratio. According to the age of children, appropriate dose of modified Yiwei decoction (treatment group) and Erbao Granule (control group), 3 times/d, for 4 weeks were given to the children. Clinical efficacy of the treatment group was observed before and after the treatment and compared with the control group. Results(①) symptom scores: Vomiting (0.061±0.024), sweating (0.140±0.004), stool (0.024±0.011), urine (0.026±0.010) in treatment group after treatment, showing statistical significance (P＜0.05) with the control group. ② disease treatment: The total effective rate was 93.3％ and 91.1％ in the treatment group and the control group, the difference was not statistically significant (X2=0.886, P＞0.05). ③symptoms treatment: The total effective rate was 95.6％ and 66.7％ in the treatment group and the control group respectively, the difference was statistically significant (x2=0.625, P＜0.05). Conclusion The treatment of modified Yiweitang was better than Erbao Granule in treating children with anorexia belonging to stomach yin deficiency.

Myocardial infarction (MI) is a cardiovascular disease with high morbidity and mortality, which seriously endangers human health. Poor ways of repair after MI may damage people's life quality, therefore scientists have been committed to exploring the way of myocardial repair after MI to strive for a better prognosis of these patients. Chinese patent medicines for blood circulation activation have a long history of use in treatment of MI, where they have been shown to attenuate myocardial injury after MI and promote cardiac repair with multiple targets, links and pathways. This review focuses on a few representative Chinese patent medicines for MI and summarizes their pharmacological effects and clinical research in cardiac repair following MI, effectively providing scientific foundation on treating MI with Chinese patent medicines.

Objective: To study the clinical efficacy of modified Zhenwutang combined with Zhengji technique on cold-dampness arthralgia syndrome caused by knee osteoarthritis (KOA) at episode and the effect on inflammatory factors of joint fluid. Method: One hundred and forty-eight patients were randomly divided into control group and observation group by random number table. Patients in control group got celecoxib capsules, 0.2 g/time, 1 time/day, and Zhengji technique with lumbar positioning oblique pulling and finger pressing for 12 times, 1 time for every two days, 3 times/week. Patients in observation group got modified Zhenwutang, 1 dose/day, and the same Zhengji technique. The course of treatment was 4 weeks. Before and after treatment, western Ontario and McMaster University Osteoarthritis index (WOMAC), pain and swelling, index of severity of osteoarthritis (ISOA), local signs of knee joint and cold-dampness obstruction syndrome were scored, and the score of quality of life were discussed by arthritis impact measurement scale 2 (AIMS2-SF). And levels of interleukin-1 beta (IL-1β), IL-17, tumor necrosis factor-alpha (TNF-α), substance P (SP) and calcitonin gene-related peptide (CGRP) were detected. Result: The clinical efficacy in observation group was better than that in control group (Z=2.131, P<0.05). Scores of pain from WOMAC scale, stiff, joint function and the total score of WOMAC were lower than those in control group (P<0.01), and scores of pain (walking pain, resting pain, tenderness), degree of swelling, ISOA, cold-dampness arthralgia syndrome and local signs of knee joint were lower than those in control group (P<0.01). And physical, symptoms, impact, social and work factor scores, the total scores of AIMS2-SF scale, IL-1β, IL-17, TNF-α, SP and CGRP were higher than those in control group (P<0.01). Conclusion: Modified Zhenwutang combined with Zhengji technique can relieve clinical symptoms of patients with cold-dampness arthralgia syndrome caused by knee osteoarthritis (KOA) at episode, ameliorate joint function to improve patients' quality of life, reduce the expression of proinflammatory factors and neuropeptides in synovial fluid, so as to inhibit the inflammatory response and controlling clinical symptoms.

Rituximab, a chimeric human-mouse monoclonal antibody, has been used as a first-line treatment for CD20

OBJECTIVE To evaluate the levels of evidence and analyze the rationality for off-label use of tacrolimus in the kidney diseases in adults. METHODS By systematically reviewing the drug instructions, clinical guidelines and medical literature of tacrolimus in the kidney diseases in adults, screening the highest level of evidence, and an evaluation table based on evidence-based medical for off-label use of tacrolimus in the kidney diseases in adults was established. Based on the evaluation table, collect adult patients from the Department of Nephrology in Zhongda Hospital Southeast University who had a medication history of off-label use of tacrolimus from January 1, 2021 to December 31, 2022, and evaluated the rationality of application for tacrolimus. RESULTS A total of 19 indications for off-label use of tacrolimus in the kidney diseases in adults were listed, and their recommended levels were determined based on evidence. Among them, the recommended levels for common types of kidney diseases were higher. In addition, 194 adult patients with off-label use of tacrolimus were selected from the Department of Nephrology in Zhongda Hospital Southeast University, and their application recommended levels with "strongly recommended""moderately strongly recommended""weakly recommended" and "not recommended", were 67.0%, 12.9%, 15.0% and 5.1%, respectively. CONCLUSION Tacrolimus has a wide range of indications for off-label use in the kidney diseases in adults, but the evidence for most common types of kidney diseases are relatively sufficient and their use are reasonable.

[Objective] To evaluate the efficacy and safety of sacral neuromodulation (SNM) in the treatment of patients with benign prostatic hyperplasia (BPH) complicated with underactive bladder (UAB) who respond poorly to transurethral resection of the prostate (TURP). [Methods] A retrospective analysis was performed on 10 patients with BPH and UAB treated with TURP by the same surgeon in Zhongda Hospital Southeast University during Jan.2018 and Jan.2023.The residual urine volume was not significantly relieved after operation, and the maximum urine flow rate and urine volume per discharge were not significantly improved.All patients underwent phase I SNM, and urinary diaries were recorded before and after surgery to observe the average daily frequency of urination, volume per urination, maximum urine flow rate, and residual urine volume. [Results] The operation time was (97.6±11.2) min.During the postoperative test of 2-4 weeks, if the residual urine volume reduction by more than 50% was deemed as effective, SNM was effective in 6 patients (60.0%). Compared with preoperative results, the daily frequency of urination [(20.2±3.8) times vs. (13.2±3.2) times], volume per urination [(119.2±56.7) mL vs. (246.5±59.2) mL], maximum urine flow rate [(8.7±1.5) mL/s vs. (16.5±2.6) mL/s], and residual urine volume [(222.5±55.0) mL vs. (80.8±16.0) mL] were significantly improved, with statistical significance (P<0.05). There were no complications such as bleeding, infection, fever or pain.The 6 patients who had effective outcomes successfully completed phase II surgery, and the fistula was removed.During the follow-up of 1 year, the curative effect was stable, and there were no complications such as electrode displacement, incision infection, or pain in the irritation sites.The residual urine volume of the other 4 unsuccessful patients did not improve significantly, and the electrodes were removed and the vesicostomy tube was retained. [Conclusion] SNM is safe and effective in the treatment of BPH with UAB patients with poor curative effects after TURP.

Extracellular vesicles (EVs) are lipid bilayer-enclosed structures containing diverse bioactive cargoes that play a major role in intercellular communication in both physiological and pathological conditions. Currently, the field of EV-based therapy has been rapidly growing, and two main therapeutic uses of EVs can be surmised: (i) exploiting stem cell-derived EVs as therapeutic agents; and (ii) employing EVs as natural therapeutic vectors for drug delivery. This review will discuss the recent advances in EV-based therapy in the treatment of renal disease.
Cell Communication ; Drug Delivery Systems ; Extracellular Vesicles ; Humans ; Kidney Diseases/therapy*

Chronic kidney disease (CKD) is becoming an alarming health burden worldwide, however, there is still lack of early biomarkers and effective treatment options. Thus, in the upcoming era of precision medicine, searching for the sensitive, non-invasive biomarkers has been the cornerstone and major challenge in the management of CKD. Urine contains rich biological information which could be an ideal source for non-invasive biomarkers of CKD. This review will discuss the recent advances in biomarker study from urine sediment, urine supernatant and urinary extracellular vesicles with special interest in gene transcript (miRNA, mRNA) biomarkers. Besides, the challenges and future directions for urinary gene transcript biomarker study will be discussed.
Biomarkers ; urine ; Humans ; MicroRNAs ; urine ; RNA, Messenger ; urine ; Renal Insufficiency, Chronic ; diagnosis ; urine

Anticholesteremic Agents/therapeutic use* ; Cholesterol, LDL ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors ; Hypolipidemic Agents/therapeutic use* ; Lipids

OBJECTIVETo isolate, culture, and identify bone marrow mesenchymal stem cells (BMSCs) from enhanced green fluorescent protein (EGFP)-transgenic rats in vitro.

METHODSBone marrows were isolated from tibia and femur of healthy EGFP-transgenic rats of specific pathogen free (SPF) grade. Then,the whole bone marrow adherent method was used for isolation,culture,and purification of BMSCs. The morphological change was noted by continuous observation under inverted fluorescence microscope. The growth curve of cells was drawn through the method of CCK-8 and the proliferation compared with wild type BMSCs. The surface markers of BMSCs were detected by flow cytometry. The BMSCs were induced to differentiate into osteoblasts, adipocytes, and chondrocytes lineages. The EGFP-BMSCs were transplanted into the rats intravenously, and the expression of GFP was detected.

RESULTSBMSCs stably expressing EGFP gene were obtained successfully, with the fusiform-shaped appearance and the forming of circinate cell colonies. The growth curve of EGFP-MSCs showed the characteristic of active proliferation, showing no significant difference compared with the wild-type BMSCs. The expression rates of the surface markers of BMSCs CD29, CD90, CD34, CD49d, and CD45 were 99.4%, 96.4%, 0.171%, 0.049%, and 0.038%. The GFP were detected in lung 3 days after transplantation. After osteogenic, adipogenic, and chondrogenic induction, oil red-O and alizarin red positive signals and toluidine blue positive cells were detected.

CONCLUSIONSHigh-purity BMSCs stably expressing green fluorescent protein gene can be cultured using the whole bone marrow adherent method. EGFP does not affect the stem cell properties and expresses stably after transplantation. The cells can be used as seed cells for subsequent research.

Adipocytes ; Animals ; Bone Marrow Cells ; Cells, Cultured ; Chondrocytes ; Flow Cytometry ; Green Fluorescent Proteins ; Hematopoietic Stem Cells ; Mesenchymal Stromal Cells ; Osteoblasts ; Rats ; Rats, Transgenic